+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID04187443

Study of MS-553 Oral Treatment in Adults with Diabetic Retinopathy and Central Macular Edema Open-label Phase 1 Dose Escalation Trial

Led by Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. · Updated on 2025-09-29

45

Participants Needed

3

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and treatment benefits of MS-553 in patients with diabetic retinopathy who have central involved macular edema. This open-label, phase 1 dose-escalation study focuses on patients who have not previously received treatment for this eye condition. The goal is to observe how different doses of MS-553 affect the condition over an 8-week period. Participants will be divided into three groups, each receiving a different oral dose of MS-553 low, mid, or high. Each dose cohort will include fifteen subjects, and all will take the medication daily for 8 weeks. The study is designed to monitor the effects of these varying doses on the eye condition and any emerging side effects. During the study, participants will undergo regular assessments including measurements of retinal thickness, retinal volume, and visual acuity using standardized eye exams. Researchers will track any treatment-emergent adverse events from the start through day 56. The study lasts approximately 8 weeks, during which safety and treatment effects will be carefully monitored to understand the impact of MS-553 on diabetic macular edema.

CONDITIONS

Brief Title

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

Research Team

L

Ling Yang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here